|
GB0110029D0
(en)
|
2001-04-24 |
2001-06-13 |
Grosveld Frank |
Transgenic animal
|
|
SI2311874T1
(sl)
*
|
2004-07-22 |
2017-12-29 |
Erasmus University Medical Center Rotterdam Department of Cell Biology and Genetics |
Vezavne molekule
|
|
TWI404727B
(zh)
*
|
2006-01-25 |
2013-08-11 |
荷蘭鹿特丹Ｅｒａｓｍｕｓ大學醫學中心 |
對偶基因排除
|
|
DK2602323T3
(en)
|
2007-06-01 |
2018-04-16 |
Open Monoclonal Tech Inc |
Compositions and Methods for Inhibiting Endogenous Immunoglobin Genes and Producing Transgenic Human Idiotypic Antibodies
|
|
WO2009013620A2
(en)
*
|
2007-06-11 |
2009-01-29 |
Erasmus University Medical Center Rotterdam |
Homologous recombination
|
|
ES2436044T3
(es)
|
2008-05-23 |
2013-12-26 |
Ablexis, Llc |
Procedimiento de generación de anticuerpos de dominio VL individual en animales transgénicos
|
|
US20100122358A1
(en)
*
|
2008-06-06 |
2010-05-13 |
Crescendo Biologics Limited |
H-Chain-only antibodies
|
|
JP5827127B2
(ja)
|
2008-12-18 |
2015-12-02 |
エラスムス・ユニヴァーシティ・メディカル・センター・ロッテルダム |
ヒト化抗体を発現する非ヒトトランスジェニック動物及びその使用
|
|
GB0905023D0
(en)
|
2009-03-24 |
2009-05-06 |
Univ Erasmus Medical Ct |
Binding molecules
|
|
US9445581B2
(en)
|
2012-03-28 |
2016-09-20 |
Kymab Limited |
Animal models and therapeutic molecules
|
|
BR112012000536A2
(pt)
|
2009-07-08 |
2020-08-11 |
Kymab Limited |
métodos para produção de anticorpo ou cadeia leve ou pesada de anticorpo específico para um antígeno desejado, para produção de anticorpo ou cadeia de anticorpo e seu uso, composição farmacêutica e derivado de anticorpo quimérico
|
|
US8754287B2
(en)
*
|
2009-12-10 |
2014-06-17 |
Regeneron Pharmaceuticals, Inc. |
Mice that make heavy chain antibodies
|
|
SI2501817T2
(sl)
|
2010-02-08 |
2021-09-30 |
Regeneron Pharmaceuticals, Inc. |
Miš z navadno lahko verigo
|
|
US9796788B2
(en)
|
2010-02-08 |
2017-10-24 |
Regeneron Pharmaceuticals, Inc. |
Mice expressing a limited immunoglobulin light chain repertoire
|
|
US20130045492A1
(en)
|
2010-02-08 |
2013-02-21 |
Regeneron Pharmaceuticals, Inc. |
Methods For Making Fully Human Bispecific Antibodies Using A Common Light Chain
|
|
SG10201912639SA
(en)
|
2010-08-02 |
2020-02-27 |
Regeneron Pharma |
Mice that make binding proteins comprising vl domains
|
|
RS59728B1
(sr)
|
2011-08-05 |
2020-02-28 |
Regeneron Pharma |
Humanizovani miševi univerzalnog lakog lanca
|
|
BR112014006394A2
(pt)
|
2011-09-19 |
2017-03-28 |
Kymab Ltd |
manipulação de diversidade genética de imunoglobulina e terapêuticos multi-anticorpos
|
|
WO2013045916A1
(en)
|
2011-09-26 |
2013-04-04 |
Kymab Limited |
Chimaeric surrogate light chains (slc) comprising human vpreb
|
|
KR20160098514A
(ko)
|
2011-10-17 |
2016-08-18 |
리제너론 파아마슈티컬스, 인크. |
제한된 면역글로불린 중쇄 마우스
|
|
US9253965B2
(en)
|
2012-03-28 |
2016-02-09 |
Kymab Limited |
Animal models and therapeutic molecules
|
|
RU2664181C2
(ru)
|
2011-12-20 |
2018-08-15 |
Регенерон Фармасьютикалз, Инк. |
Мыши с гуманизированной легкой цепью
|
|
US10251377B2
(en)
|
2012-03-28 |
2019-04-09 |
Kymab Limited |
Transgenic non-human vertebrate for the expression of class-switched, fully human, antibodies
|
|
GB2502127A
(en)
*
|
2012-05-17 |
2013-11-20 |
Kymab Ltd |
Multivalent antibodies and in vivo methods for their production
|
|
PT3597037T
(pt)
|
2012-06-12 |
2021-06-01 |
Regeneron Pharma |
Animais não humanos humanizados com lócus de cadeia pesada de imunoglobulina restrito
|
|
HRP20231356T1
(hr)
|
2012-12-14 |
2024-02-16 |
Omniab, Inc. |
Polinukleotidi koji kodiraju protutijela glodavaca s ljudskim idiotipovima i životinje koje ih sadrže
|
|
EP2840892B1
(en)
|
2013-02-20 |
2018-04-18 |
Regeneron Pharmaceuticals, Inc. |
Non-human animals with modified immunoglobulin heavy chain sequences
|
|
US9980470B2
(en)
|
2013-03-14 |
2018-05-29 |
Erasmus University Medical Center |
Antibody production
|
|
US10993420B2
(en)
|
2013-03-15 |
2021-05-04 |
Erasmus University Medical Center |
Production of heavy chain only antibodies in transgenic mammals
|
|
US9788534B2
(en)
|
2013-03-18 |
2017-10-17 |
Kymab Limited |
Animal models and therapeutic molecules
|
|
US9783618B2
(en)
|
2013-05-01 |
2017-10-10 |
Kymab Limited |
Manipulation of immunoglobulin gene diversity and multi-antibody therapeutics
|
|
US11707056B2
(en)
|
2013-05-02 |
2023-07-25 |
Kymab Limited |
Animals, repertoires and methods
|
|
US9783593B2
(en)
|
2013-05-02 |
2017-10-10 |
Kymab Limited |
Antibodies, variable domains and chains tailored for human use
|
|
DE112014004537T5
(de)
|
2013-10-01 |
2016-07-21 |
Kymab Limited |
Tiermodelle und therapeutische Moleküle
|
|
KR102276752B1
(ko)
|
2014-03-21 |
2021-07-13 |
리제너론 파마슈티칼스 인코포레이티드 |
단일 도메인 결합 단백질을 생산하는 비-인간 동물
|
|
WO2015143406A2
(en)
|
2014-03-21 |
2015-09-24 |
Regeneron Pharmaceuticals, Inc. |
Vl antigen binding proteins exhibiting distinct binding characteristics
|
|
EP3271403A1
(en)
|
2015-03-19 |
2018-01-24 |
Regeneron Pharmaceuticals, Inc. |
Non-human animals that select for light chain variable regions that bind antigen
|
|
US10266589B2
(en)
|
2015-07-29 |
2019-04-23 |
Allergan, Inc. |
Heavy chain only antibodies to ANG-2
|
|
CN105384825B
(zh)
|
2015-08-11 |
2018-06-01 |
南京传奇生物科技有限公司 |
一种基于单域抗体的双特异性嵌合抗原受体及其应用
|
|
WO2017030909A1
(en)
|
2015-08-14 |
2017-02-23 |
Allergan, Inc. |
Heavy chain only antibodies to pdgf
|
|
CA2997444A1
(en)
|
2015-09-29 |
2017-04-06 |
Amgen Inc. |
Asgr inhibitors for reducing cholesterol levels
|
|
WO2018014260A1
(en)
|
2016-07-20 |
2018-01-25 |
Nanjing Legend Biotech Co., Ltd. |
Multispecific antigen binding proteins and methods of use thereof
|
|
EP4282877A3
(en)
|
2016-08-10 |
2024-02-21 |
Legend Biotech Ireland Limited |
Chimeric antigen receptors targeting bcma and methods of use thereof
|
|
WO2018068201A1
(en)
|
2016-10-11 |
2018-04-19 |
Nanjing Legend Biotech Co., Ltd. |
Single-domain antibodies and variants thereof against ctla-4
|
|
EP3332637A1
(en)
*
|
2016-12-09 |
2018-06-13 |
Universitätsklinikum Hamburg-Eppendorf |
Vhh-containing heavy chain antibody and production thereof
|
|
NZ755816A
(en)
|
2017-01-19 |
2026-03-27 |
Omniab Inc |
Human antibodies from transgenic rodents with multiple heavy chain immunoglobulin loci
|
|
WO2019000223A1
(en)
|
2017-06-27 |
2019-01-03 |
Nanjing Legend Biotech Co., Ltd. |
ENABLERS OF IMMUNE EFFECTOR CELLS OF CHIMERIC ANTIBODIES AND METHODS OF USE THEREOF
|
|
TW201930358A
(zh)
|
2017-12-28 |
2019-08-01 |
大陸商南京傳奇生物科技有限公司 |
針對ｔｉｇｉｔ之單域抗體及其變異體
|
|
KR102845020B1
(ko)
|
2017-12-28 |
2025-08-12 |
난징 레전드 바이오테크 씨오., 엘티디. |
Pd-l1에 대한 항체 및 변이체
|
|
EP3740507A4
(en)
|
2018-01-15 |
2022-08-24 |
Nanjing Legend Biotech Co., Ltd. |
SINGLE DOMAIN ANTIBODIES AND VARIANTS THEREOF AGAINST PD-1
|
|
MA51996A
(fr)
|
2018-03-13 |
2021-01-20 |
Smivet B V |
Anticorps à domaine unique se liant à la neurotoxine tétanique
|
|
CN108486125B
(zh)
*
|
2018-03-27 |
2024-01-05 |
重庆金迈博生物科技有限公司 |
一种核酸分子及其在制备人源单域抗体中的应用
|
|
AU2019241350B2
(en)
|
2018-03-30 |
2025-10-02 |
Nanjing Legend Biotech Co., Ltd. |
Single-domain antibodies against LAG-3 and uses thereof
|
|
KR20210056288A
(ko)
|
2018-06-01 |
2021-05-18 |
타유 후아시아 바이오테크 메디컬 그룹 컴퍼니 리미티드 |
질환 또는 병태를 치료하기 위한 조성물 및 그의 용도
|
|
WO2019227490A1
(en)
|
2018-06-01 |
2019-12-05 |
Tayu Huaxia Biotech Medical Group Co., Ltd. |
Compositions and methods for imaging
|
|
AU2019284252B2
(en)
|
2018-06-13 |
2025-10-09 |
Crystal Bioscience Inc. |
Production of antibodies by modification of an autonomous heavy chain variable domain by gene conversion
|
|
US12097219B2
(en)
|
2018-09-10 |
2024-09-24 |
Legend Biotech Ireland Limited |
Single-domain antibodies against CLL1 and constructs thereof
|
|
WO2020151572A1
(en)
|
2019-01-23 |
2020-07-30 |
Tayu Huaxia Biotech Medical Group Co., Ltd. |
Anti-pd-l1 diabodies and the use thereof
|
|
CN113874394B
(zh)
|
2019-02-20 |
2024-01-19 |
和铂抗体有限公司 |
抗体
|
|
MA56110A
(fr)
|
2019-06-07 |
2022-04-13 |
Amgen Inc |
Constructions de liaison bispécifiques à lieurs clivables de manière sélective
|
|
CN110818795B
(zh)
|
2020-01-10 |
2020-04-24 |
上海复宏汉霖生物技术股份有限公司 |
抗tigit抗体和使用方法
|
|
EP4097144A4
(en)
*
|
2020-01-28 |
2024-02-28 |
University of Southern California |
Genome engineering the human immunoglobulin locus to express recombinant binding domain molecules
|
|
CA3169910A1
(en)
|
2020-02-28 |
2021-09-02 |
Shanghai Henlius Biotech, Inc. |
Anti-cd137 constructs, multispecific antibody and uses thereof
|
|
AU2021225920A1
(en)
|
2020-02-28 |
2022-09-15 |
Shanghai Henlius Biotech, Inc. |
Anti-CD137 construct and use thereof
|
|
GB202003632D0
(en)
|
2020-03-12 |
2020-04-29 |
Harbour Antibodies Bv |
SARS-Cov-2 (SARS2, COVID-19) antibodies
|
|
CN116529260A
(zh)
|
2020-06-02 |
2023-08-01 |
当康生物技术有限责任公司 |
抗cd93构建体及其用途
|
|
US20230235075A1
(en)
|
2020-06-02 |
2023-07-27 |
Dynamicure Biotechnology Llc |
Anti-cd93 constructs and uses thereof
|
|
CA3184351A1
(en)
|
2020-06-04 |
2021-12-09 |
Amgen Inc. |
Bispecific binding constructs
|
|
US11981932B2
(en)
|
2020-06-17 |
2024-05-14 |
Janssen Biotech, Inc. |
Materials and methods for the manufacture of pluripotent stem cells
|
|
US20230322953A1
(en)
|
2020-06-30 |
2023-10-12 |
Harbour Biomed (Shanghai) Co., Ltd |
Binding protein having h2l2 and hcab structures
|
|
WO2022002038A1
(zh)
|
2020-06-30 |
2022-01-06 |
和铂医药(上海)有限责任公司 |
免疫细胞衔接器多特异性结合蛋白及其制备和应用
|
|
US20230270086A1
(en)
*
|
2020-07-13 |
2023-08-31 |
Kisoji Biotechnology Inc. |
Transgenic animals expressing heavy chain antibodies
|
|
JP7846667B2
(ja)
|
2020-07-16 |
2026-04-15 |
レジェンド バイオテック アイルランド リミテッド |
Ｃｄ２０結合分子及びその使用
|
|
TWI905235B
(zh)
|
2020-07-29 |
2025-11-21 |
美商當康生物科技有限公司 |
抗cd93之構築體及其用途
|
|
EP4192481A4
(en)
|
2020-08-10 |
2024-09-11 |
Janssen Biotech, Inc. |
MATERIALS AND METHODS FOR THE PRODUCTION OF VIRUS-SPECIFIC BIOMODIFIED LYMPHOCYTES
|
|
CN114134144A
(zh)
*
|
2020-09-04 |
2022-03-04 |
北京仁源欣生生物科技有限公司 |
一种非人哺乳动物或其子代的制备方法及其应用
|
|
AU2021348613B2
(en)
|
2020-09-28 |
2026-04-02 |
Angitia Incorporated Limited |
Anti-sclerostin constructs and uses thereof
|
|
US11484027B2
(en)
|
2020-10-29 |
2022-11-01 |
Industrial Polymers and Chemicals, Inc. |
Air filter with pathogen monitoring and inactivation
|
|
GB202017555D0
(en)
|
2020-11-06 |
2020-12-23 |
Harbour Antibodies Bv |
Antibody-conjugated nanoparticles
|
|
WO2022116877A1
(en)
|
2020-12-02 |
2022-06-09 |
Shanghai Henlius Biotech, Inc. |
ANTI-GARP/TGFβ ANTIBODIES AND METHODS OF USE
|
|
EP4255931A1
(en)
|
2020-12-03 |
2023-10-11 |
Amgen Inc. |
Immunoglobuline constructs with multiple binding domains
|
|
CA3204101A1
(en)
*
|
2020-12-09 |
2022-06-16 |
Trianni, Inc. |
Heavy chain-only antibodies
|
|
MX2023009717A
(es)
|
2021-02-19 |
2024-01-08 |
Shaperon Inc |
Anticuerpo de dominio individual contra cúmulo de diferenciación 47 (cd47) y uso del mismo.
|
|
MX2023009715A
(es)
|
2021-02-19 |
2024-01-08 |
Shaperon Inc |
Anticuerpo de dominio individual biespecífico contra el ligando de muerte programada (pd-l1) y el cúmulo de diferenciación 47 (cd47) y uso del mismo.
|
|
JP7773238B2
(ja)
|
2021-02-19 |
2025-11-19 |
シャペロン インク． |
Ｐｄ－ｌ１に対する単一ドメイン抗体及びその用途
|
|
JP2024509191A
(ja)
|
2021-03-05 |
2024-02-29 |
ダイナミキュア バイオテクノロジー エルエルシー |
抗ｖｉｓｔａ構築物およびその使用
|
|
EP4314049A1
(en)
|
2021-03-25 |
2024-02-07 |
Dynamicure Biotechnology LLC |
Anti-igfbp7 constructs and uses thereof
|
|
EP4355785A1
(en)
|
2021-06-17 |
2024-04-24 |
Amberstone Biosciences, Inc. |
Anti-cd3 constructs and uses thereof
|
|
US20230174651A1
(en)
|
2021-06-23 |
2023-06-08 |
Janssen Biotech, Inc. |
Materials and methods for hinge regions in functional exogenous receptors
|
|
WO2023036982A1
(en)
|
2021-09-10 |
2023-03-16 |
Harbour Antibodies Bv |
Anti-sars2-s antibodies
|
|
GB202112935D0
(en)
|
2021-09-10 |
2021-10-27 |
Harbour Antibodies Bv |
Sars-cov-2 (sars2, covid-19) heavy chain only antibodies
|
|
JP2025501522A
(ja)
|
2021-12-17 |
2025-01-22 |
シャンハイ・ヘンリウス・バイオテック・インコーポレイテッド |
抗ｏｘ４０抗体及び使用方法
|
|
CN118488965A
(zh)
|
2021-12-17 |
2024-08-13 |
上海复宏汉霖生物技术股份有限公司 |
抗ox40抗体、多特异性抗体及其使用方法
|
|
JP2025514610A
(ja)
|
2022-03-25 |
2025-05-09 |
シャンハイ・ヘンリウス・バイオテック・インコーポレイテッド |
抗ｍｓｌｎ抗体及び使用方法
|
|
CA3262611A1
(en)
|
2022-07-22 |
2024-01-25 |
Janssen Biotech, Inc. |
IMPROVED TRANSFER OF GENETIC INSTRUCTIONS TO EFFECTOR IMMUNE CELLS
|
|
WO2024054929A1
(en)
|
2022-09-07 |
2024-03-14 |
Dynamicure Biotechnology Llc |
Anti-vista constructs and uses thereof
|
|
WO2025034806A1
(en)
|
2023-08-08 |
2025-02-13 |
Wisconsin Alumni Research Foundation |
Single-domain antibodies and variants thereof against fibroblast activation protein
|
|
EP4512243A1
(en)
*
|
2023-08-21 |
2025-02-26 |
Kymab Limited |
Binding molecules
|
|
WO2025045250A1
(en)
|
2023-09-03 |
2025-03-06 |
Kira Pharmaceuticals (Us) Llc |
Anti-human factor d antibody constructs and uses thereof
|
|
WO2025154058A1
(en)
*
|
2024-01-21 |
2025-07-24 |
Ibi-Ag Innovative Bio Insecticides Ltd. |
Anti-insect hsp70 nanobodies and uses thereof
|
|
WO2025178959A1
(en)
|
2024-02-20 |
2025-08-28 |
University Of Georgia Research Foundation, Inc. |
Single-domain antibodies and variants thereof against tab1
|
|
GB202406483D0
(en)
|
2024-05-09 |
2024-06-26 |
Harbour Antibodies Bv |
Crossing the blood brain barrier to treat diseases of the brain
|
|
WO2025245494A1
(en)
|
2024-05-24 |
2025-11-27 |
Regeneron Pharmaceuticals, Inc. |
Tumor-targeted split il12 receptor agonists
|
|
US20250376524A1
(en)
|
2024-06-07 |
2025-12-11 |
Regeneron Pharmaceuticals, Inc. |
Tetravalent multispecific binding molecules and methods of use thereof
|
|
WO2025255452A2
(en)
|
2024-06-07 |
2025-12-11 |
Regeneron Pharmaceuticals, Inc. |
Antigen-binding molecules that bind to aav particles and uses thereof
|
|
WO2026035843A2
(en)
*
|
2024-08-06 |
2026-02-12 |
Regeneron Pharmaceuticals, Inc. |
Non-human animals having modified immunoglobulin heavy chain constant region locus and uses thereof
|
|
WO2026039791A1
(en)
|
2024-08-16 |
2026-02-19 |
Regeneron Pharmaceuticals, Inc. |
Tumor-targeted split il2 receptor agonists
|
|
WO2026076013A1
(en)
|
2024-10-01 |
2026-04-09 |
Regeneron Pharmaceuticals, Inc. |
Tumor-targeted il2 receptor agonists and multispecific t-cell engagers
|
|
WO2026075989A1
(en)
|
2024-10-01 |
2026-04-09 |
Regeneron Pharmaceuticals, Inc. |
Engineered igg molecules and methods of use thereof
|